Faslodex Spermiogenesis Inhibitor

Alternative Name: Antiestrogen ICI 182780; Fulvestrant

Description: Faslodex induces infertility by diluting epididymal sperm, without blocking the reproductive tract. Targets estrogen receptor-alpha, dominant in only one region of the male reproductive tract in rats, but not dogs or marmosets at non-toxic doses-- the efferent ductules. Does not target the androgen receptor or testosterone, the dominant male hormone pathway.

Product Details

User: Male

Hormonal: Yes

Delivery Method: Injectable

Duration Type: Short-acting

Multipurpose Preventive Technology (MPT): No

Status Details

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Pre-clinical

Active Development: No

Status Details:
  • Active ingredient already FDA-approved and on market for the treatment of breast cancer in women. Pre-clinical proof-of-concept studies conducted for male contraceptive use.

Additional Information

References:
  • Cho HW, Nie R, et al. (2003). The antiestrogen ICI 182, 780 induces early effects on the adult male mouse reproductive tract and long-term decreased fertility without testicular atrophy. Reprod Biol Endocrinol 1(1): 57.

Vertical Tabs

Print